Rethinking ovarian cancer III: the past decade and future directions - Nature
Rethinking ovarian cancer III: the past decade and future directions Nature
Ovarian Cancer News
Sandy Sprint 5K returns to Philly Navy Yard, marks 25 years of ovarian cancer fight - FOX 29 Philadelphia
Sandy Sprint 5K returns to Philly Navy Yard, marks 25 years of ovarian cancer fight FOX 29 Philadelphia
Netball: Manchester Thunder's Sophie Fawns reflects on her mum's cancer and moving to the UK - bbc.com
Netball: Manchester Thunder's Sophie Fawns reflects on her mum's cancer and moving to the UK bbc.com
GSK reports promising early results in ovarian and womb cancer drug trial - The Guardian
GSK reports promising early results in ovarian and womb cancer drug trial The Guardian
GSK advancing ovarian cancer drug mo-rez - statnews.com
GSK advancing ovarian cancer drug mo-rez statnews.com
GSK fast-tracks cancer drug that may add billions in annual sales - The Times
GSK fast-tracks cancer drug that may add billions in annual sales The Times
Some With Low-Grade Serous Ovarian Cancer May Not Need Chemo - Medscape
Some With Low-Grade Serous Ovarian Cancer May Not Need Chemo Medscape
Genetic testing leads to early diagnosis of ovarian cancer: Sally’s story - Roswell Park Comprehensive Cancer Center
Genetic testing leads to early diagnosis of ovarian cancer: Sally’s story Roswell Park Comprehensive Cancer Center
REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer - CancerNetwork
REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer CancerNetwork
Combining new drug with chemotherapy extends survival of platinum-resistant ovarian cancer patients in clinical trial - Medical Xpress
Combining new drug with chemotherapy extends survival of platinum-resistant ovarian cancer patients in clinical trial Medical Xpress
Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO - BioSpace
Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO BioSpace
Repurposed drug may extend survival in aggressive ovarian cancer, trial shows - The Guardian
Repurposed drug may extend survival in aggressive ovarian cancer, trial shows The Guardian
Expanding HIPEC for Ovarian Cancer Through Hands-On Training - Cleveland Clinic
Expanding HIPEC for Ovarian Cancer Through Hands-On Training Cleveland Clinic
ADC Demonstrates Early Promise in Multiple Cancer Types - Oncology News Central
ADC Demonstrates Early Promise in Multiple Cancer Types Oncology News Central
Mirvetuximab Soravtansine Combo Elicits Antitumor Activity in Platinum-Sensitive Ovarian Cancer - Targeted Oncology
Mirvetuximab Soravtansine Combo Elicits Antitumor Activity in Platinum-Sensitive Ovarian Cancer Targeted Oncology
OCRF Invites Teams to Support Ovarian Cancer Research Campaigns - Oncodaily
OCRF Invites Teams to Support Ovarian Cancer Research Campaigns Oncodaily
Rezatapopt Shows Activity in Pretreated Ovarian Cancer With TP53 Mutation - Cure Today
Rezatapopt Shows Activity in Pretreated Ovarian Cancer With TP53 Mutation Cure Today
Relacorilant Plus Nab-Paclitaxel Significantly Improves OS in Platinum-Resistant Ovarian Cancer - OncLive
Relacorilant Plus Nab-Paclitaxel Significantly Improves OS in Platinum-Resistant Ovarian Cancer OncLive
AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial - Clinical Trials Arena
AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial Clinical Trials Arena
Novel B7H3 ADC Yields Responses in Cervical Cancer and Platinum-Resistant Ovarian Cancer - CancerNetwork
Novel B7H3 ADC Yields Responses in Cervical Cancer and Platinum-Resistant Ovarian Cancer CancerNetwork
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer - OncLive
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer OncLive
Dr Monk on the KEYNOTE-B96 Data in Recurrent Platinum-Resistant Ovarian Cancer - OncLive
Dr Monk on the KEYNOTE-B96 Data in Recurrent Platinum-Resistant Ovarian Cancer OncLive
Rezatapopt Generates Rapid, Durable Responses Across Subgroups in Pretreated TP53 Y220C-Mutated Ovarian Cancer - OncLive
Rezatapopt Generates Rapid, Durable Responses Across Subgroups in Pretreated TP53 Y220C-Mutated Ovarian Cancer OncLive
Dr Olawaiye on the Final OS Data From the Phase 3 ROSELLA Trial in Platinum-Resistant Ovarian Cancer - OncLive
Dr Olawaiye on the Final OS Data From the Phase 3 ROSELLA Trial in Platinum-Resistant Ovarian Cancer OncLive
AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story - Yahoo Finance
AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story Yahoo Finance
Facilitated Cascade Genetic Testing: A New Standard of Care? - Medscape
Facilitated Cascade Genetic Testing: A New Standard of Care? Medscape
Florida Cancer Specialists & Research Institute Contributes to Milestone that Expands Treatment Options For Patients With Recurrent Ovarian Cancer - PR Newswire
Florida Cancer Specialists & Research Institute Contributes to Milestone that Expands Treatment Options For Patients With Recurrent Ovarian Cancer PR Newswire
New research links radon exposure to ovarian cancer - WXYZ Channel 7
New research links radon exposure to ovarian cancer WXYZ Channel 7
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer - OncLive
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer OncLive
Study shows survival benefit of immunotherapy in resistant ovarian cancer - Medical Xpress
Study shows survival benefit of immunotherapy in resistant ovarian cancer Medical Xpress
Letrozole monotherapy falls short in ovarian cancer clinical trial - News-Medical
Letrozole monotherapy falls short in ovarian cancer clinical trial News-Medical
Data backs GSK's ovarian cancer blockbuster hopes - pharmaphorum
Data backs GSK's ovarian cancer blockbuster hopes pharmaphorum
Phase 3 Survival Data Show Combo Regimen Is a “Game Changer” for Ovarian Cancer - Oncology News Central
Phase 3 Survival Data Show Combo Regimen Is a “Game Changer” for Ovarian Cancer Oncology News Central
Chemo Combo Wins in Ovarian Cancer, but Single-Agent Therapy Still in the Game - MedPage Today
Chemo Combo Wins in Ovarian Cancer, but Single-Agent Therapy Still in the Game MedPage Today
25-Year-Old's Pain Dismissed as Acid Reflux, Later Diagnosed as Ovarian Cancer (Exclusive) - People.com
25-Year-Old's Pain Dismissed as Acid Reflux, Later Diagnosed as Ovarian Cancer (Exclusive) People.com
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers - GSK US
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers GSK US
GSK sees blockbuster potential in targeted cancer therapy after promising early data - Reuters
GSK sees blockbuster potential in targeted cancer therapy after promising early data Reuters
AbbVie ovarian cancer drug shows 62.7% response rate in trial - Investing.com
AbbVie ovarian cancer drug shows 62.7% response rate in trial Investing.com
Radon and Ovarian Cancer; FDA Rejects Drug Again; Missed Chances for Genomic Testing - MedPage Today
Radon and Ovarian Cancer; FDA Rejects Drug Again; Missed Chances for Genomic Testing MedPage Today
Radon Gas Increases Risk Of Ovarian Cancer, Study Says - HealthDay
Radon Gas Increases Risk Of Ovarian Cancer, Study Says HealthDay